Steven Salamon - Oct 30, 2024 Form 4 Insider Report for DELCATH SYSTEMS, INC. (DCTH)

Role
Director
Signature
Steven Salamon
Stock symbol
DCTH
Transactions as of
Oct 30, 2024
Transactions value $
$500,000
Form type
4
Date filed
11/1/2024, 03:20 PM
Previous filing
May 28, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCTH Tranche B warrants to purchase F-4 Preferred Stock Options Exercise $500K +500 $1,000.00 0 Oct 30, 2024 F-4 PREFERRED STOCK 500 $1,000.00 By Rosalind Advisors, Inc., the advisor to the Rosalind Funds F1, F2, F3
transaction DCTH 8% CONVERTIBLE NOTE Expiration (or cancellation) of long derivative position with value received $0 0 $0.00 0 Oct 30, 2024 CASH $1.42M $0.00 By Rosalind Advisors, Inc., the advisor to the Rosalind Funds F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable
F2 The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024.
F3 Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein
F4 N/A
F5 Delcath repaid the DELCATH SYSTEM - 8% CONVERTIBLE NOTE in full with cash of $1,423,333.